Trial Profile
A Phase-Ib Dose-Finding Study of the SMAC Mimetic Debio 1143 When Given in Combination With the Anti-PD-L1 Antibody Avelumab to Patients With Advanced Solid Malignancies and, in an Expansion Cohort, to Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 May 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Xevinapant (Primary)
- Indications Adenocarcinoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Debiopharm
- 19 Apr 2023 Results om a phase 1b dose-expansion cohort of xevinapant, a first-in-class, oral, small-molecule IAP (inhibitor of apoptosis protein) inhibitor that restores cancer cell sensitivity to apoptosis, and avelumab (anti-PD-L1) in pts with advanced NSCLC presented at the 114th Annual Meeting of the American Association for Cancer Research
- 31 Mar 2022 Status changed from active, no longer recruiting to completed.
- 21 Oct 2021 Planned End Date changed from 1 Feb 2022 to 1 Mar 2022.